FarmaKology-Mushroom Supplement Found to Slow Prostate Cancer
Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to "abdul@farmakology.com", and happy to have you featured on our newsletter+21K Subs.
Today's Company
Autolus Therapeutics
Autolus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
News
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics Inc., a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement (CRADA) has been executed to advance the development of camonsertib as an anticancer agent in collaboration with the Cancer Therapy Evaluation Program (CTEP) of the US National Cancer Institute (NCI), part of the US National Institutes of Health.
U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The FDA has cleared the Company to begin enrolling the planned Phase 3 trial following the determination that Novavax satisfactorily addressed all clinical hold issues. Novavax will be working with the clinical trial investigators and other partners to resume trial activities as quickly as possible.
Nutcracker Therapeutics Introduces CRDMO Precision Biomanufacturing Solutions for RNA Drug Developers
Nutcracker Therapeutics, Inc., a pioneering biotechnology company dedicated to enabling transformative RNA therapies through its proprietary technology platform, today announced its new contract research, development, and manufacturing organization (CRDMO) capabilities, which will provide next-generation design and biomanufacturing solutions for RNA drug developers.
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
Cytokinetics Incorporated today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose clinical study of CK-4015089 (CK-089) in healthy human participants. CK-089 is a fast skeletal muscle troponin activator (FSTA) with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired muscle function.
Research & Study
New cancer therapy strategy targets GLUT3 in regulatory T cells to supercharge anti-tumor immunity
Mushroom Supplement Found to Slow Prostate Cancer
Vitamin D supplements during pregnancy improve child bone health
Podcast
Job Opportunities
Medical Representative
Pharmacy Technician
clinical pharmacist
Pharmacist
Upcoming Webinar & Event
Biologic therapies: Charting the path from injectables to inhalation
Dose Administration, Compatibility, and Clinical Usability of Biologics
Video
